Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The inherited or acquired deregulation of protein kinase activity has been implicated in the pathogenesis of many human diseases, including cancer. Therefore, the inhibition of kinases has been proposed to be a promising strategy in the context of anti-cancer treatment. Many other kinases have been selected as drug discovery targets based on the prevalence of mutations, over-expression and unscheduled activation in human cancer. Of the various protein kinases chosen, Src family kinases are amongst the most extensively studied kinase oncogenes in academia and industry. This review focuses on our current understanding of the deregulation and role of Src family kinases in human cancer and leukemia. Recent data implicate the action of c-Src in cancer metastasis, mediated by up-regulation of various protease systems (calpain, uPA) as well as disruption of E-cadherin signalling. Moreover, novel roles of various Src family members in the development of human leukemia have been found. New insights into downstream signalling mechanisms, including the activation of STAT3, PDK1 and Akt, further corroborate the importance of Src family kinases in tumorigenesis and chemoresistance. Despite our rather clear understanding of Src family kinases as pro-oncogenes no Src family kinase inhibitor has entered a clinical trial so far. This review will discuss prerequisites to be fulfilled for clinically targeting c-Src and its homologues using small molecule drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“Further analysis of patient samples suggested that the mechanisms of resistance are diverse, including gene amplification, point mutations that interfere with STI571 binding, clonal evolution due to secondary mutations and the up-regulation of signalling molecules such as Btk [120-125].”
BackgroundDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase
Schlaepfer, D. D., Hanks, S. K., Hunter, T., & Geer, P. V. D. (1994) · Nature · doi:10.1038/372786a0 · Cited by 1,595
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“Two recent publications suggest that this is a rather common occurrence when working with small molecule kinase inhibitors [157, 158], questioning not only results on Src signalling but also on the function of many other kinases obtained by using small molecule kinase inhibitors.”
BackgroundStat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation
Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., & Jove, R. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2545 · Cited by 651
Stat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489 · cited 2×
“In support of this, it was shown that a subset of human colon cancer patients posses a mutant Src allele that lacks the negative-regulatory tyrosine phosphorylation site [18].”
Background
Cited by
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344
Cowan-Jacob, S. W., Fendrich, G., Manley, P. W., Jahnke, W., Fabbro, D., Liebetanz, J., & Meyer, T. (2005) · Structure · doi:10.1016/j.str.2005.03.012 · Cited by 335
Self-citationNew Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Demetri, G. D., Lo Russo, P., MacPherson, I. R. J., Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agrawal, S., Voi, M., & Evans, T. R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0224 · Cited by 150
Metadata
- Authors
- Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., & Gray, N.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-10-01
- Volume
- 9
- Issue
- 25
- Pages
- 2043-2059
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2146275677
- Cited by
- 107
- References
- 22
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. https://app.cochat.ai/papers/10.2174/1381612033454126
- The paper
- Warmuth, M., Damoiseaux, R., Liu, Y., Fabbro, D., & Gray, N. (2003). Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Current Pharmaceutical Design. https://doi.org/10.2174/1381612033454126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.